Media requests should be directed to: 

Katy Riddick, Voices of Alzheimer’s Secretariat  

E-mail: kriddick@highlanterngroup.com 

Phone: +1 202 223 2027 

FOR IMMEDIATE RELEASE 

OUR MINDS. OUR LIVES. OUR CHOICES. 

Amid the Discontinuation of Biogen’s Aduhelm, We Urge Biogen to  
Prioritize Patient Support  

We are disappointed by the news that Biogen has opted to terminate its Alzheimer’s disease therapy, Aduhelm, ending treatment for all patients currently being prescribed the drug.  More information about the announcement is available here.   

We understand that this is a business decision rooted in financial costs, and not reflective of the safety nor efficacy of this breakthrough class of Alzheimer’s treatments, but among the Voices of Alzheimer’s community, we know the deep personal impact for patients who have benefited from this drug.  This includes founding VoA Board members Geri Taylor and Phil Gutis, along with many others.   Aduhelm was the first in a series of innovations that have brought improvement and optimism to its countless patients’ lives, for which we are deeply grateful. 

Regardless of Biogen’s decision to cut Aduhelm, we recognize that Biogen has been a pioneer in Alzheimer’s research and treatment and continues to work on new treatments – including with their partner, Eisai, on another disease modifying therapy, Leqembi.  

As patient advocates, we remain concerned that individuals currently taking Aduhelm will face difficulty in finding new treatment options. We urge Biogen to use this moment to set a precedent for patient care and education in response to discontinuing Aduhelm.  It is imperative that Alzheimer’s patients and their care partners receive clear and accessible information about this change, centering on the patient experience. Those impacted by Alzheimer’s disease should have access to educational information about what the end of Aduhelm means for patients as well as resources on how patients can effectively strategize with their doctor and care partner to develop a new treatment plan.  

We are experiencing a pivotal moment in Alzheimer’s treatments, with remarkable progress being made. However, in the face of tremendous change we cannot neglect the priorities of Alzheimer’s patients. Their needs must consistently be at the forefront in every aspect of treatment development and implementation. 

Learn more on the Voices of Alzheimer’s website, and on social media through Facebook, Twitter, Instagram, and TikTok.   
  

VoicesOfAD.com